The expression levels of IL-27 and IL-27Rα were significantly reduced in psoriasis patients in both protein and RNA levels. Topical administration with IL-27 can alleviate the clinical manifestation of imiquimod-induced mouse model. IL-27 could suppress the function of Th17 cells in imiquimod-induced mouse models.